Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $16.50.

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. lowered Neumora Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Royal Bank of Canada cut shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $29.00 to $4.00 in a research note on Thursday, January 2nd. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Neumora Therapeutics in a research report on Friday. Bank of America lowered their price target on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a report on Thursday, January 2nd.

Neumora Therapeutics Stock Performance

Shares of NASDAQ NMRA opened at $2.48 on Thursday. The firm has a fifty day moving average of $10.28 and a 200 day moving average of $11.46. The firm has a market cap of $400.67 million, a PE ratio of -1.33 and a beta of 2.71. Neumora Therapeutics has a one year low of $1.83 and a one year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period in the previous year, the business posted ($1.14) EPS. On average, equities analysts predict that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Matthew K. Fust sold 14,049 shares of the company’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the transaction, the director now owns 20,100 shares of the company’s stock, valued at $342,303. This represents a 41.14 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Robert A. Lenz sold 5,563 shares of the firm’s stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total value of $83,500.63. Following the sale, the insider now directly owns 322,966 shares of the company’s stock, valued at $4,847,719.66. The trade was a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its holdings in Neumora Therapeutics by 2.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company’s stock valued at $851,000 after purchasing an additional 1,629 shares during the last quarter. Barclays PLC grew its stake in shares of Neumora Therapeutics by 352.9% in the third quarter. Barclays PLC now owns 129,210 shares of the company’s stock valued at $1,708,000 after buying an additional 100,678 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Neumora Therapeutics by 54.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock valued at $26,159,000 after buying an additional 694,385 shares during the period. Wexford Capital LP lifted its stake in Neumora Therapeutics by 90.1% during the 3rd quarter. Wexford Capital LP now owns 217,879 shares of the company’s stock worth $2,878,000 after acquiring an additional 103,285 shares in the last quarter. Finally, State Street Corp boosted its holdings in Neumora Therapeutics by 65.3% during the 3rd quarter. State Street Corp now owns 1,790,707 shares of the company’s stock valued at $23,655,000 after acquiring an additional 707,409 shares during the period. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.